Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and inhibition in the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.
Binimetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethyl)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, and an apoptosis inducer. It is a member of benzimidazoles, a member of bromobenzenes, a member of monofluorobenzenes, a hydroxamic acid ester, and a secondary amino compound.
Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor that is combined with [Encorafenib]. On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Mechanism of Action
Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. The inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors. This process can result in the inhibition of growth factor-mediated cell signaling. This may lead to the inhibition of tumor cell proliferation and inhibition in the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor. MEK1/2 are themselves threonine and tyrosine kinases that possess a dual specificity. They subsequently contribute critically to the activation of the RAS/RAF/MEK/ERK pathway and are typically upregulated in a number of different tumor cell types.
Binimetinib is a MEK inhibitor. MEK is an enzyme that regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. MEK inhibitors interfere with these biosynthetic processes. It is a chemotherapeutic agent that has anti-tumor activity
Indications
- Food and Drug Administration approved encorafenib and binimetinib in combination with patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Treatment of colorectal carcinoma
- Treatment of melanoma
- Metastatic Melanoma
- Unresectable Melanoma
Use in Cancer
Binimetinib is approved to be used with encorafenib to treat:
- Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer has a certain mutation in the BRAF gene.
Binimetinib is also being studied in the treatment of other types of cancer.
Contraindications
- chronic heart failure
- blood clot formation in vein
- bleeding
- liver problems
- a condition with muscle tissue breakdown called rhabdomyolysis
- pregnancy
- a patient who is producing milk and breastfeeding
- lung tissue problem
Dosage
Strengths: 15 mg
Melanoma – Metastatic
- 45 mg orally every 12 hours in combination with encorafenib until disease progression or unacceptable toxicity
- Refer to the encorafenib prescribing information for encorafenib dosing information.
- This drug may be taken with or without food.
- Do not take a missed dose within 6 hours of the next dose.
- Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose.
Liver Dose Adjustments
- Mild hepatic impairment (total bilirubin greater than 1 and less than or equal to 1.5 x the upper limit of normal (ULN) and any AST or total bilirubin less than or equal to ULN and AST greater than ULN: No adjustment recommended.
- Moderate (total bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than or equal to 3 × ULN and any AST) hepatic impairment: The recommended dose is 30 mg orally 2 times a day.
Dose Adjustments
If encorafenib is permanently discontinued, discontinue this drug.
Recommended Dose Reductions for Adverse Reactions:
- First dose reduction: 30 mg orally every 12 hours
- Subsequent modification: Permanently discontinue this drug if unable to tolerate 30 mg orally every 12 hours.
DOSE ADJUSTMENTS:
CARDIOMYOPATHY:
- Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN): Withhold this drug for up to 4 weeks; evaluate LVEF every 2 weeks. Resume this drug at a reduced dose if LVEF is at or above the lower limit or normal AND absolute decrease from baseline is 10% or less AND patient is asymptomatic. If the LVEF does not recover within 4 weeks permanently discontinue this drug.
- Symptomatic congestive heart failure or absolute decrease in LVEF or greater than 20% from baseline that is also below LLN: Permanently discontinue this drug.
VENOUS THROMBOEMBOLISM:
- Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE): Withhold this drug. If improves to Grade 0 or 1, resume at a reduced dose. If no improvement, permanently discontinue this drug.
- Life-threatening PE: Permanently discontinue this drug.
SEROUS RETINOPATHY:
- Symptomatic serous retinopathy/retinal pigment epithelial detachments: Withhold this drug for up to 10 days. If improves and becomes asymptomatic, resume at the same dose. If not improved, resume at a lower dose level or permanently discontinue this drug.
RETINAL VEIN OCCLUSION (RVO):
- Any grade: Permanently discontinue this drug.
UVEITIS:
- Grade 1, 2, or 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks. If improved, resume at same or reduced dose. If not improved, permanently discontinue this drug.
- Grade 4: Permanently discontinue this drug.
INTERSTITIAL LUNG DISEASE:
- Grade 2: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1, resume a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
- Grade 3 or 4: Permanently discontinue this drug.
HEPATOTOXICITY:
- Grade 2 AST or ALT increased: Maintain the dose. If no improvement within 2 weeks, withhold this drug until improved to Grade 0 or 1 or to pretreatment/baseline levels and then resume at the same dose.
- First occurrence of Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, resume at reduced dose. If no improvement, permanently discontinue this drug.
- Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug.
- First occurrence of Grade 4 AST or ALT increased: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.
- Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug.
RHABDOMYOLYSIS OR CREATINE PHOSPHOKINASE (CPK) ELEVATIONS:
- Grade 4 asymptomatic CPK elevation OR any Grade CPK elevation with symptoms or with renal impairment: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
DERMATOLOGIC:
- Grade 2: If no improvement within 2 weeks, withhold this drug until Grades 0 to 1. Resume at the same dose if the first occurrence or reduce the dose if recurrent.
- Grade 3: Withhold this drug until Grade 0 or 1. Resume at the same dose if the first occurrence or reduce dose if recurrent.
- Grade 4: Permanently discontinue this drug.
OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE):
- Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
- The first occurrence of any Grade 4: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.
Side Effects
The Most Common
- fatigue, nausea, diarrhea, vomiting,
- abdominal pain, and arthralgia.
- hemorrhage and headache.
- Retinal hemorrhage, retinal detachment (6%),
- macular edema, serous retinopathy (20%)
- Hypertension,
- thromboembolic events such as DVT, resulting in pulmonary embolism (5.6%),
- peripheral edema or periorbital edema (43.5%),
- hemorrhage (11.2%)
- Pulmonary events
- Pneumonitis (1.9%),
- Pulmonary embolism
- Cardiovascular system QT interval prolongation (3.3%),
- Left ventricular dysfunction (7%)
- Gastrointestinal system
- Hepatotoxicity, diarrhea, nausea, vomiting,
- stomatitis, dry mouth
- Acneiform dermatitis
More Common
- fatigue
- nausea
- diarrhea
- vomiting
- abdominal pain
- constipation
- dizziness
- vision changes or eye pain, swelling, or redness
- fever, sore throat, chills, cough, or other signs of infection
- yellow eyes or skin, dark urine, loss of appetite, fatigue, or pain or discomfort in right upper stomach area
- unusual weakness, muscle pain, or dark red or brown urine
- unusual bleeding or bruising; black, tarry, or bloody stools; or coughing up blood
- shortness of breath or cough
- sudden onset of difficulty breathing; chest pain; swelling of the feet, ankles, or lower legs; or leg pain, warmth, or swelling
- fast, pounding heartbeat; shortness of breath; swelling of ankles and feet; or dizziness
Rare
- Anemia
- Vomiting
- Increased AST/ALT
- Abdominal pain
- Constipation
- Rash
- Increased alkaline phosphatase
- Visual impairment
- Serous retinopathy/retinal pigment epithelial dystrophy (RPED)
- Bleeding
- Low blood sodium (hyponatremia)
- Fever
- Dizziness
- Low white blood cell count (leukopenia, neutropenia)
- Low lymphocyte levels (lymphopenia)
- Swelling of extremities
- Increased GGT
- High blood pressure (hypertension)
- Colitis
- Panniculitis
- Drug hypersensitivity
Drug interaction
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Binimetinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Binimetinib can be increased when combined with Abatacept. |
| Abiraterone | The serum concentration of Binimetinib can be increased when it is combined with Abiraterone. |
| Abrocitinib | The serum concentration of Binimetinib can be increased when it is combined with Abrocitinib. |
| Acenocoumarol | The metabolism of Binimetinib can be decreased when combined with Acenocoumarol. |
| Acetaminophen | The metabolism of Binimetinib can be decreased when combined with Acetaminophen. |
| Acyclovir | The metabolism of Binimetinib can be decreased when combined with Acyclovir. |
| Adalimumab | The metabolism of Binimetinib can be increased when combined with Adalimumab. |
| Adenine | The metabolism of Binimetinib can be decreased when combined with Adenine. |
| Afatinib | The serum concentration of Binimetinib can be increased when it is combined with Afatinib. |
| Agomelatine | The metabolism of Binimetinib can be decreased when combined with Agomelatine. |
| Albendazole | The metabolism of Binimetinib can be increased when combined with Albendazole. |
| Alosetron | The metabolism of Binimetinib can be decreased when combined with Alosetron. |
| Ambrisentan | The serum concentration of Binimetinib can be increased when it is combined with Ambrisentan. |
| Aminophenazone | The metabolism of Binimetinib can be decreased when combined with Aminophenazone. |
| Aminophylline | The metabolism of Binimetinib can be decreased when combined with Aminophylline. |
| Amiodarone | The serum concentration of Binimetinib can be increased when it is combined with Amiodarone. |
| Amitriptyline | The metabolism of Binimetinib can be decreased when combined with Amitriptyline. |
| Anagrelide | The metabolism of Binimetinib can be decreased when combined with Anagrelide. |
| Anakinra | The metabolism of Binimetinib can be increased when combined with Anakinra. |
| Antipyrine | The metabolism of Binimetinib can be decreased when combined with Antipyrine. |
| Apalutamide | The serum concentration of Binimetinib can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Binimetinib can be increased when it is combined with Apixaban. |
| Apremilast | The metabolism of Binimetinib can be increased when combined with Apremilast. |
| Armodafinil | The metabolism of Binimetinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Binimetinib can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Articaine. |
| Asciminib | The serum concentration of Binimetinib can be increased when it is combined with Asciminib. |
| Asenapine | The metabolism of Binimetinib can be decreased when combined with Asenapine. |
| Asunaprevir | The serum concentration of Binimetinib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The metabolism of Binimetinib can be decreased when combined with Atazanavir. |
| Avanafil | The serum concentration of Binimetinib can be increased when it is combined with Avanafil. |
| Avatrombopag | The serum concentration of Binimetinib can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Binimetinib can be decreased when combined with Axitinib. |
| Azathioprine | The metabolism of Binimetinib can be decreased when combined with Azathioprine. |
| Azelastine | The metabolism of Binimetinib can be decreased when combined with Azelastine. |
| Belantamab mafodotin | The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin. |
| Belinostat | The serum concentration of Binimetinib can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Binimetinib can be increased when it is combined with Belumosudil. |
| Bendamustine | The metabolism of Binimetinib can be decreased when combined with Bendamustine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Benzyl alcohol. |
| Berotralstat | The serum concentration of Binimetinib can be increased when it is combined with Berotralstat. |
| Betaxolol | The metabolism of Binimetinib can be decreased when combined with Betaxolol. |
| Betrixaban | The serum concentration of Binimetinib can be increased when it is combined with Betrixaban. |
| Bimekizumab | The metabolism of Binimetinib can be increased when combined with Bimekizumab. |
| Bisoprolol | The serum concentration of Binimetinib can be increased when it is combined with Bisoprolol. |
| Bortezomib | The metabolism of Binimetinib can be decreased when combined with Bortezomib. |
| Bromazepam | The metabolism of Binimetinib can be decreased when combined with Bromazepam. |
| Bromotheophylline | The metabolism of Bromotheophylline can be decreased when combined with Binimetinib. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Bupivacaine. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Butamben. |
| Cabazitaxel | The serum concentration of Binimetinib can be increased when it is combined with Cabazitaxel. |
| Caffeine | The metabolism of Binimetinib can be decreased when combined with Caffeine. |
| Canagliflozin | The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Binimetinib can be increased when combined with Canakinumab. |
| Cannabidiol | The metabolism of Binimetinib can be decreased when combined with Cannabidiol. |
| Capmatinib | The serum concentration of Binimetinib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Binimetinib can be increased when combined with Carbamazepine. |
| Carfilzomib | The serum concentration of Binimetinib can be increased when it is combined with Carfilzomib. |
| Carmustine | The metabolism of Binimetinib can be decreased when combined with Carmustine. |
| Carvedilol | The serum concentration of Binimetinib can be increased when it is combined with Carvedilol. |
| Ceritinib | The serum concentration of Binimetinib can be increased when it is combined with Ceritinib. |
| Certolizumab pegol | The metabolism of Binimetinib can be increased when combined with Certolizumab pegol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Chloroprocaine. |
| Chlorpromazine | The metabolism of Binimetinib can be decreased when combined with Chlorpromazine. |
| Chlorzoxazone | The metabolism of Binimetinib can be decreased when combined with Chlorzoxazone. |
| Cilostazol | The metabolism of Binimetinib can be decreased when combined with Cilostazol. |
| Cimetidine | The metabolism of Binimetinib can be decreased when combined with Cimetidine. |
| Cinacalcet | The metabolism of Binimetinib can be decreased when combined with Cinacalcet. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Cinchocaine. |
| Cinnarizine | The metabolism of Binimetinib can be decreased when combined with Cinnarizine. |
| Cinoxacin | The metabolism of Binimetinib can be decreased when combined with Cinoxacin. |
| Ciprofloxacin | The metabolism of Binimetinib can be decreased when combined with Ciprofloxacin. |
| Citalopram | The metabolism of Binimetinib can be decreased when combined with Citalopram. |
| Clarithromycin | The serum concentration of Binimetinib can be increased when it is combined with Clarithromycin. |
| Clobazam | The serum concentration of Binimetinib can be increased when it is combined with Clobazam. |
| Clofazimine | The serum concentration of Binimetinib can be increased when it is combined with Clofazimine. |
| Clomifene | The serum concentration of Binimetinib can be increased when it is combined with Clomifene. |
| Clomipramine | The metabolism of Binimetinib can be decreased when combined with Clomipramine. |
| Clonidine | The metabolism of Binimetinib can be decreased when combined with Clonidine. |
| Clopidogrel | The metabolism of Binimetinib can be decreased when combined with Clopidogrel. |
| Clozapine | The metabolism of Binimetinib can be decreased when combined with Clozapine. |
| Cobicistat | The serum concentration of Binimetinib can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Binimetinib can be increased when it is combined with Cobimetinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Cocaine. |
| Colchicine | The serum concentration of Binimetinib can be increased when it is combined with Colchicine. |
| Conivaptan | The serum concentration of Binimetinib can be increased when it is combined with Conivaptan. |
| Conjugated estrogens | The metabolism of Binimetinib can be decreased when combined with Conjugated estrogens. |
| Copanlisib | The serum concentration of Binimetinib can be increased when it is combined with Copanlisib. |
| Crizotinib | The serum concentration of Binimetinib can be increased when it is combined with Crizotinib. |
| Curcumin | The serum concentration of Binimetinib can be increased when it is combined with Curcumin. |
| Cyclobenzaprine | The metabolism of Binimetinib can be decreased when combined with Cyclobenzaprine. |
| Cyclosporine | The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine. |
| Cyproterone acetate | The metabolism of Binimetinib can be increased when combined with Cyproterone acetate. |
| Dabigatran etexilate | The serum concentration of Binimetinib can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The metabolism of Binimetinib can be decreased when combined with Dabrafenib. |
| Dacarbazine | The metabolism of Binimetinib can be decreased when combined with Dacarbazine. |
| Daclatasvir | The serum concentration of Binimetinib can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Binimetinib can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Binimetinib can be increased when it is combined with Dactinomycin. |
| Dapagliflozin | The metabolism of Binimetinib can be decreased when combined with Dapagliflozin. |
| Daptomycin | The serum concentration of Binimetinib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binimetinib. |
| Darolutamide | The serum concentration of Binimetinib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Binimetinib can be increased when it is combined with Darunavir. |
| Dasabuvir | The metabolism of Binimetinib can be decreased when combined with Dasabuvir. |
| Dasatinib | The metabolism of Binimetinib can be decreased when combined with Dasatinib. |
| Deferasirox | The serum concentration of Binimetinib can be increased when it is combined with Deferasirox. |
| Desogestrel | The metabolism of Binimetinib can be increased when combined with Desogestrel. |
| Dexamethasone acetate | The serum concentration of Binimetinib can be decreased when it is combined with Dexamethasone acetate. |
| Dexfenfluramine | The metabolism of Binimetinib can be decreased when combined with Dexfenfluramine. |
| Dexmedetomidine | The metabolism of Binimetinib can be decreased when combined with Dexmedetomidine. |
| Diacerein | The metabolism of Binimetinib can be decreased when combined with Diacerein. |
| Diclofenac | The metabolism of Binimetinib can be decreased when combined with Diclofenac. |
| Digitoxin | The serum concentration of Binimetinib can be increased when it is combined with Digitoxin. |
| Digoxin | The serum concentration of Binimetinib can be increased when it is combined with Digoxin. |
| Dihydralazine | The metabolism of Binimetinib can be decreased when combined with Dihydralazine. |
| Diosmin | The serum concentration of Binimetinib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Diphenhydramine. |
| Disopyramide | The metabolism of Binimetinib can be decreased when combined with Disopyramide. |
| Dolutegravir | The serum concentration of Binimetinib can be increased when it is combined with Dolutegravir. |
| Domperidone | The metabolism of Binimetinib can be decreased when combined with Domperidone. |
| Dosulepin | The metabolism of Binimetinib can be decreased when combined with Dosulepin. |
| Doxepin | The metabolism of Binimetinib can be decreased when combined with Doxepin. |
| Dronabinol | The metabolism of Binimetinib can be decreased when combined with Dronabinol. |
| Dronedarone | The serum concentration of Binimetinib can be increased when it is combined with Dronedarone. |
| Duvelisib | The serum concentration of Binimetinib can be increased when it is combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Dyclonine. |
| Edoxaban | The serum concentration of Binimetinib can be increased when it is combined with Edoxaban. |
| Efavirenz | The metabolism of Binimetinib can be increased when combined with Efavirenz. |
| Elagolix | The serum concentration of Binimetinib can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Binimetinib can be increased when it is combined with Elbasvir. |
| Eliglustat | The serum concentration of Binimetinib can be increased when it is combined with Eliglustat. |
| Eltrombopag | The metabolism of Binimetinib can be decreased when combined with Eltrombopag. |
| Emapalumab | The metabolism of Binimetinib can be increased when combined with Emapalumab. |
| Enasidenib | The serum concentration of Binimetinib can be increased when it is combined with Enasidenib. |
| Enfortumab vedotin | The serum concentration of Binimetinib can be increased when it is combined with Enfortumab vedotin. |
| Enoxacin | The metabolism of Binimetinib can be decreased when combined with Enoxacin. |
| Entecavir | The metabolism of Binimetinib can be decreased when combined with Entecavir. |
| Entrectinib | The serum concentration of Binimetinib can be increased when it is combined with Entrectinib. |
| Erdafitinib | The serum concentration of Binimetinib can be increased when it is combined with Erdafitinib. |
| Erlotinib | The metabolism of Binimetinib can be decreased when combined with Erlotinib. |
| Ertugliflozin | The metabolism of Binimetinib can be decreased when combined with Ertugliflozin. |
| Erythromycin | The serum concentration of Binimetinib can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Binimetinib. |
| Estradiol | The metabolism of Binimetinib can be decreased when combined with Estradiol. |
| Estradiol acetate | The metabolism of Binimetinib can be decreased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Estradiol benzoate can be decreased when combined with Binimetinib. |
| Estradiol cypionate | The metabolism of Estradiol cypionate can be decreased when combined with Binimetinib. |
| Estradiol dienanthate | The metabolism of Estradiol dienanthate can be decreased when combined with Binimetinib. |
| Estradiol valerate | The metabolism of Estradiol valerate can be decreased when combined with Binimetinib. |
| Estrone sulfate | The metabolism of Binimetinib can be decreased when combined with Estrone sulfate. |
| Etanercept | The metabolism of Binimetinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Binimetinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Binimetinib can be decreased when combined with Ethanol. |
| Ethinylestradiol | The metabolism of Binimetinib can be increased when combined with Ethinylestradiol. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Etidocaine. |
| Etoposide | The metabolism of Binimetinib can be decreased when combined with Etoposide. |
| Etoricoxib | The metabolism of Binimetinib can be decreased when combined with Etoricoxib. |
| Everolimus | The serum concentration of Binimetinib can be increased when it is combined with Everolimus. |
| Famotidine | The metabolism of Binimetinib can be decreased when combined with Famotidine. |
| Favipiravir | The serum concentration of Binimetinib can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Binimetinib can be increased when it is combined with Fedratinib. |
| Fenfluramine | The metabolism of Binimetinib can be decreased when combined with Fenfluramine. |
| Fexinidazole | The metabolism of Binimetinib can be decreased when combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Binimetinib can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Binimetinib can be increased when it is combined with Filgotinib. |
| Flecainide | The metabolism of Binimetinib can be decreased when combined with Flecainide. |
| Flibanserin | The serum concentration of Binimetinib can be increased when it is combined with Flibanserin. |
| Fluconazole | The serum concentration of Binimetinib can be increased when it is combined with Fluconazole. |
| Flunarizine | The metabolism of Binimetinib can be decreased when combined with Flunarizine. |
| Flunitrazepam | The metabolism of Binimetinib can be decreased when combined with Flunitrazepam. |
| Fluorouracil | The metabolism of Binimetinib can be decreased when combined with Fluorouracil. |
| Fluoxetine | The metabolism of Binimetinib can be decreased when combined with Fluoxetine. |
| Flurbiprofen | The metabolism of Binimetinib can be decreased when combined with Flurbiprofen. |
| Flutamide | The metabolism of Binimetinib can be decreased when combined with Flutamide. |
| Fluvoxamine | The metabolism of Binimetinib can be decreased when combined with Fluvoxamine. |
| Fosphenytoin | The metabolism of Binimetinib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Binimetinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | The serum concentration of Binimetinib can be increased when it is combined with Fostemsavir. |
| Frovatriptan | The metabolism of Binimetinib can be decreased when combined with Frovatriptan. |
| Futibatinib | The serum concentration of Binimetinib can be increased when it is combined with Futibatinib. |
| Gatifloxacin | The metabolism of Binimetinib can be decreased when combined with Gatifloxacin. |
| Gemcitabine | The serum concentration of Binimetinib can be increased when it is combined with Gemcitabine. |
| Gemfibrozil | The metabolism of Binimetinib can be decreased when combined with Gemfibrozil. |
| Gemifloxacin | The metabolism of Binimetinib can be decreased when combined with Gemifloxacin. |
| Gilteritinib | The serum concentration of Binimetinib can be increased when it is combined with Gilteritinib. |
| Givosiran | The serum concentration of Binimetinib can be increased when it is combined with Givosiran. |
| Glasdegib | The serum concentration of Binimetinib can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Binimetinib can be increased when it is combined with Glecaprevir. |
| Golimumab | The metabolism of Binimetinib can be increased when combined with Golimumab. |
| Grazoprevir | The serum concentration of Binimetinib can be increased when it is combined with Grazoprevir. |
| Grepafloxacin | The metabolism of Binimetinib can be decreased when combined with Grepafloxacin. |
| Guanabenz | The metabolism of Binimetinib can be decreased when combined with Guanabenz. |
| Haloperidol | The metabolism of Binimetinib can be decreased when combined with Haloperidol. |
| Idelalisib | The serum concentration of Binimetinib can be increased when it is combined with Idelalisib. |
| Imatinib | The metabolism of Binimetinib can be decreased when combined with Imatinib. |
| Imipramine | The metabolism of Binimetinib can be decreased when combined with Imipramine. |
| Indacaterol | The serum concentration of Binimetinib can be increased when it is combined with Indacaterol. |
| Indinavir | The metabolism of Binimetinib can be decreased when combined with Indinavir. |
| Indomethacin | The metabolism of Binimetinib can be decreased when combined with Indomethacin. |
| Infliximab | The metabolism of Binimetinib can be increased when combined with Infliximab. |
| Inotuzumab ozogamicin | The serum concentration of Binimetinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Insulin beef | The metabolism of Binimetinib can be increased when combined with Insulin beef. |
| Insulin pork | The metabolism of Binimetinib can be increased when combined with Insulin pork. |
| Interferon alfa-2a | The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2a. |
| Interferon alfa-2b | The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2b. |
| Interferon alfa-n1 | The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n1. |
| Interferon alfa-n3 | The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n3. |
| Interferon alfacon-1 | The metabolism of Binimetinib can be decreased when combined with Interferon alfacon-1. |
| Interferon beta-1a | The metabolism of Binimetinib can be decreased when combined with Interferon beta-1a. |
| Interferon beta-1b | The metabolism of Binimetinib can be decreased when combined with Interferon beta-1b. |
| Interferon gamma-1b | The metabolism of Binimetinib can be decreased when combined with Interferon gamma-1b. |
| Isavuconazole | The serum concentration of Binimetinib can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Binimetinib can be increased when it is combined with Isavuconazonium. |
| Isoniazid | The metabolism of Binimetinib can be decreased when combined with Isoniazid. |
| Istradefylline | The serum concentration of Binimetinib can be increased when it is combined with Istradefylline. |
| Itraconazole | The serum concentration of Binimetinib can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Binimetinib can be increased when it is combined with Ivacaftor. |
| Ixabepilone | The serum concentration of Binimetinib can be increased when it is combined with Ixabepilone. |
| Ketoconazole | The serum concentration of Binimetinib can be increased when it is combined with Ketoconazole. |
| Lamotrigine | The metabolism of Binimetinib can be increased when combined with Lamotrigine. |
| Lapatinib | The serum concentration of Binimetinib can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Binimetinib can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Binimetinib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Binimetinib can be increased when it is combined with Ledipasvir. |
| Lefamulin | The serum concentration of Binimetinib can be increased when it is combined with Lefamulin. |
| Leflunomide | The serum concentration of Binimetinib can be decreased when it is combined with Leflunomide. |
| Lemborexant | The serum concentration of Binimetinib can be increased when it is combined with Lemborexant. |
| Lenvatinib | The serum concentration of Binimetinib can be increased when it is combined with Lenvatinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Binimetinib can be increased when it is combined with Levoketoconazole. |
| Levothyroxine | The serum concentration of Binimetinib can be decreased when it is combined with Levothyroxine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Lidocaine. |
| Linagliptin | The serum concentration of Binimetinib can be increased when it is combined with Linagliptin. |
| Lofexidine | The metabolism of Binimetinib can be decreased when combined with Lofexidine. |
| Lomefloxacin | The metabolism of Binimetinib can be decreased when combined with Lomefloxacin. |
| Lomitapide | The serum concentration of Binimetinib can be increased when it is combined with Lomitapide. |
| Lonafarnib | The serum concentration of Binimetinib can be increased when it is combined with Lonafarnib. |
| Lonapegsomatropin | The metabolism of Binimetinib can be increased when combined with Lonapegsomatropin. |
| Loncastuximab tesirine | The serum concentration of Binimetinib can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The serum concentration of Binimetinib can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Binimetinib can be increased when it is combined with Lopinavir. |
| Lorcaserin | The metabolism of Binimetinib can be decreased when combined with Lorcaserin. |
| Lorlatinib | The serum concentration of Binimetinib can be decreased when it is combined with Lorlatinib. |
| Loxapine | The serum concentration of Binimetinib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Binimetinib can be decreased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Binimetinib can be increased when it is combined with Lusutrombopag. |
| Mannitol | The serum concentration of Binimetinib can be increased when it is combined with Mannitol. |
| Maprotiline | The metabolism of Binimetinib can be decreased when combined with Maprotiline. |
| Maribavir | The serum concentration of Binimetinib can be increased when it is combined with Maribavir. |
| Mefenamic acid | The metabolism of Binimetinib can be decreased when combined with Mefenamic acid. |
| Mefloquine | The serum concentration of Binimetinib can be increased when it is combined with Mefloquine. |
| Melatonin | The metabolism of Binimetinib can be decreased when combined with Melatonin. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Meloxicam. |
| Mephenytoin | The metabolism of Binimetinib can be decreased when combined with Mephenytoin. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Mepivacaine. |
| Methimazole | The metabolism of Binimetinib can be decreased when combined with Methimazole. |
| Methoxsalen | The metabolism of Binimetinib can be decreased when combined with Methoxsalen. |
| Methoxy polyethylene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Binimetinib. |
| Methylene blue | The serum concentration of Binimetinib can be increased when it is combined with Methylene blue. |
| Metoclopramide | The metabolism of Binimetinib can be decreased when combined with Metoclopramide. |
| Mexiletine | The metabolism of Binimetinib can be decreased when combined with Mexiletine. |
| Mianserin | The metabolism of Binimetinib can be decreased when combined with Mianserin. |
| Mifepristone | The serum concentration of Binimetinib can be decreased when it is combined with Mifepristone. |
| Mirabegron | The serum concentration of Binimetinib can be increased when it is combined with Mirabegron. |
| Mirtazapine | The metabolism of Binimetinib can be decreased when combined with Mirtazapine. |
| Mitapivat | The metabolism of Binimetinib can be increased when combined with Mitapivat. |
| Morphine | The serum concentration of Binimetinib can be increased when it is combined with Morphine. |
| Moxifloxacin | The metabolism of Binimetinib can be decreased when combined with Moxifloxacin. |
| Nabumetone | The metabolism of Binimetinib can be decreased when combined with Nabumetone. |
| Nafcillin | The metabolism of Binimetinib can be increased when combined with Nafcillin. |
| Nalidixic acid | The metabolism of Binimetinib can be decreased when combined with Nalidixic acid. |
| Naproxen | The metabolism of Binimetinib can be decreased when combined with Naproxen. |
| Nelfinavir | The metabolism of Binimetinib can be increased when combined with Nelfinavir. |
| Neratinib | The serum concentration of Binimetinib can be increased when it is combined with Neratinib. |
| Netupitant | The serum concentration of Binimetinib can be increased when it is combined with Netupitant. |
| Nevirapine | The metabolism of Binimetinib can be decreased when combined with Nevirapine. |
| Niclosamide | The metabolism of Binimetinib can be decreased when combined with Niclosamide. |
| Nifedipine | The metabolism of Binimetinib can be decreased when combined with Nifedipine. |
| Nilotinib | The serum concentration of Binimetinib can be increased when it is combined with Nilotinib. |
| Nintedanib | The serum concentration of Binimetinib can be increased when it is combined with Nintedanib. |
| Norfloxacin | The metabolism of Binimetinib can be decreased when combined with Norfloxacin. |
| Norgestimate | The serum concentration of Binimetinib can be increased when it is combined with Norgestimate. |
| Obeticholic acid | The metabolism of Binimetinib can be decreased when combined with Obeticholic acid. |
| Olanzapine | The metabolism of Binimetinib can be decreased when combined with Olanzapine. |
| Omadacycline | The serum concentration of Binimetinib can be increased when it is combined with Omadacycline. |
| Ombitasvir | The metabolism of Binimetinib can be decreased when combined with Ombitasvir. |
| Omeprazole | The metabolism of Binimetinib can be increased when combined with Omeprazole. |
| Ondansetron | The metabolism of Binimetinib can be decreased when combined with Ondansetron. |
| Orphenadrine | The metabolism of Binimetinib can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Binimetinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The serum concentration of Binimetinib can be decreased when it is combined with Osimertinib. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Oxetacaine. |
| Oxtriphylline | The metabolism of Binimetinib can be decreased when combined with Oxtriphylline. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Oxybuprocaine. |
| Pacritinib | The serum concentration of Binimetinib can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Binimetinib can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Binimetinib can be increased when it is combined with Paliperidone. |
| Panobinostat | The serum concentration of Binimetinib can be increased when it is combined with Panobinostat. |
| Paritaprevir | The metabolism of Binimetinib can be decreased when combined with Paritaprevir. |
| Paroxetine | The metabolism of Binimetinib can be decreased when combined with Paroxetine. |
| Pazopanib | The metabolism of Binimetinib can be decreased when combined with Pazopanib. |
| Pefloxacin | The metabolism of Binimetinib can be decreased when combined with Pefloxacin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Binimetinib. |
| Peginterferon alfa-2a | The metabolism of Binimetinib can be decreased when combined with Peginterferon alfa-2a. |
| Peginterferon alfa-2b | The serum concentration of Binimetinib can be increased when it is combined with Peginterferon alfa-2b. |
| Pemetrexed | The metabolism of Binimetinib can be decreased when combined with Pemetrexed. |
| Penciclovir | The metabolism of Binimetinib can be decreased when combined with Penciclovir. |
| Pentoxifylline | The metabolism of Binimetinib can be decreased when combined with Pentoxifylline. |
| Perampanel | The metabolism of Binimetinib can be decreased when combined with Perampanel. |
| Perphenazine | The metabolism of Binimetinib can be decreased when combined with Perphenazine. |
| Pexidartinib | The metabolism of Binimetinib can be decreased when combined with Pexidartinib. |
| Phenobarbital | The metabolism of Binimetinib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Phenol. |
| Phenylephrine | The metabolism of Binimetinib can be increased when combined with Phenylephrine. |
| Phenytoin | The metabolism of Binimetinib can be increased when combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Binimetinib can be increased when it is combined with Pibrentasvir. |
| Pimozide | The metabolism of Binimetinib can be decreased when combined with Pimozide. |
| Pirfenidone | The metabolism of Binimetinib can be decreased when combined with Pirfenidone. |
| Pitolisant | The metabolism of Binimetinib can be increased when combined with Pitolisant. |
| Pomalidomide | The metabolism of Binimetinib can be decreased when combined with Pomalidomide. |
| Ponatinib | The serum concentration of Binimetinib can be increased when it is combined with Ponatinib. |
| Posaconazole | The serum concentration of Binimetinib can be increased when it is combined with Posaconazole. |
| Pralsetinib | The serum concentration of Binimetinib can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Pramocaine. |
| Pravastatin | The serum concentration of Binimetinib can be increased when it is combined with Pravastatin. |
| Praziquantel | The metabolism of Binimetinib can be decreased when combined with Praziquantel. |
| Prednisolone | The serum concentration of Binimetinib can be decreased when it is combined with Prednisolone phosphate. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Prilocaine. |
| Primaquine | The metabolism of Binimetinib can be increased when combined with Primaquine. |
| Primidone | The metabolism of Binimetinib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Binimetinib can be decreased when combined with Probenecid. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Procaine. |
| Promazine | The metabolism of Binimetinib can be decreased when combined with Promazine. |
| Propafenone | The serum concentration of Binimetinib can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Proparacaine. |
| Propofol | The metabolism of Binimetinib can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Propoxycaine. |
| Propranolol | The metabolism of Binimetinib can be decreased when combined with Propranolol. |
| Quinidine | The serum concentration of Binimetinib can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Binimetinib can be increased when it is combined with Quinine. |
| Ramelteon | The metabolism of Binimetinib can be decreased when combined with Ramelteon. |
| Ranitidine | The metabolism of Binimetinib can be decreased when combined with Ranitidine. |
| Ranolazine | The serum concentration of Binimetinib can be increased when it is combined with Ranolazine. |
| Rasagiline | The metabolism of Binimetinib can be decreased when combined with Rasagiline. |
| Regorafenib | The serum concentration of Binimetinib can be increased when it is combined with Regorafenib. |
| Relugolix | The serum concentration of Binimetinib can be increased when it is combined with Relugolix. |
| Reserpine | The serum concentration of Binimetinib can be increased when it is combined with Reserpine. |
| Revefenacin | The serum concentration of Binimetinib can be increased when it is combined with Revefenacin. |
| Rifampicin | The serum concentration of Binimetinib can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Binimetinib can be increased when it is combined with Rifamycin. |
| Rilonacept | The metabolism of Binimetinib can be increased when combined with Rilonacept. |
| Riluzole | The metabolism of Binimetinib can be decreased when combined with Riluzole. |
| Rimegepant | The serum concentration of Binimetinib can be increased when it is combined with Rimegepant. |
| Riociguat | The serum concentration of Binimetinib can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Binimetinib can be increased when it is combined with Ripretinib. |
| Ritonavir | The serum concentration of Binimetinib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Binimetinib can be increased when it is combined with Rivaroxaban. |
| Rofecoxib | The metabolism of Binimetinib can be decreased when combined with Rofecoxib. |
| Roflumilast | The metabolism of Binimetinib can be decreased when combined with Roflumilast. |
| Rolapitant | The serum concentration of Binimetinib can be increased when it is combined with Rolapitant. |
| Romidepsin | The serum concentration of Binimetinib can be increased when it is combined with Romidepsin. |
| Ropeginterferon alfa-2b | The metabolism of Binimetinib can be decreased when combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Ropivacaine. |
| Rosoxacin | The metabolism of Binimetinib can be decreased when combined with Rosoxacin. |
| Rucaparib | The metabolism of Binimetinib can be increased when combined with Rucaparib. |
| Sapropterin | The serum concentration of Binimetinib can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Binimetinib can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Binimetinib can be increased when it is combined with Sarecycline. |
| Satralizumab | The serum concentration of Binimetinib can be decreased when it is combined with Satralizumab. |
| Secukinumab | The metabolism of Binimetinib can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Binimetinib can be decreased when combined with Selegiline. |
| Selexipag | The serum concentration of Binimetinib can be increased when it is combined with Selexipag. |
| Selumetinib | The metabolism of Binimetinib can be decreased when combined with Selumetinib. |
| Sildenafil | The serum concentration of Binimetinib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Binimetinib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Binimetinib can be increased when combined with Siltuximab. |
| Simeprevir | The serum concentration of Binimetinib can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Binimetinib can be increased when it is combined with Simvastatin. |
| Sirolimus | The serum concentration of Binimetinib can be increased when it is combined with Sirolimus. |
| Sitagliptin | The serum concentration of Binimetinib can be increased when it is combined with Sitagliptin. |
| Sodium aurothiomalate | The metabolism of Binimetinib can be decreased when combined with Sodium aurothiomalate. |
| Sofosbuvir | The serum concentration of Binimetinib can be increased when it is combined with Sofosbuvir. |
| Somapacitan | The metabolism of Binimetinib can be increased when combined with Somapacitan. |
| Somatotropin | The metabolism of Binimetinib can be increased when combined with Somatotropin. |
| Somatrem | The metabolism of Binimetinib can be increased when combined with Somatrem. |
| Somatrogon | The metabolism of Binimetinib can be increased when combined with Somatrogon. |
| Sorafenib | The serum concentration of Binimetinib can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Binimetinib can be increased when it is combined with Sotagliflozin. |
| Sotorasib | The serum concentration of Binimetinib can be increased when it is combined with Sotorasib. |
| St. John’s Wort | The serum concentration of Binimetinib can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The serum concentration of Binimetinib can be increased when it is combined with Stiripentol. |
| Suvorexant | The serum concentration of Binimetinib can be increased when it is combined with Suvorexant. |
| Tacrine | The metabolism of Binimetinib can be decreased when combined with Tacrine. |
| Tacrolimus | The serum concentration of Binimetinib can be increased when it is combined with Tacrolimus. |
Pregnancy and Lactation
US FDA pregnancy category Not Assigned
Pregnancy
Drugs that have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.
The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Lactation
No information is available on the use of this drug during breastfeeding. Because it is highly bound to plasma proteins, and the half-life is 3.5 hours, the amount in milk is likely to be low; however, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 3 days after. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during therapy and for at least 2 weeks after.
How should this medicine be used?
Binimetinib comes as a tablet to take by mouth. It is usually taken with or without food twice daily, approximately 12 hours apart. Take binimetinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take binimetinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
If you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.
Your doctor may decrease or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with binimetinib.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking binimetinib,
- tell your doctor and pharmacist if you are allergic to binimetinib, any other medications, or any of the ingredients in binimetinib tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had heart or liver disease.
- tell your doctor if you are pregnant or plan to become pregnant. You will have to take a pregnancy test before starting treatment. You should use birth control to prevent pregnancy during your treatment with binimetinib and for 30 days after your final dose. Talk to your doctor about methods of birth control that will work for you. If you become pregnant while taking binimetinib, call your doctor immediately. Binimetinib may harm the fetus.
- tell your doctor if you are breastfeeding. Do not breastfeed while you are taking binimetinib and for 3 days after your final dose.
References
